Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from MicroPort Scientific ( (HK:0853) ) is now available.
MicroPort Scientific Corporation announced that the New England Journal of Medicine and the European Society of Cardiology Congress have published findings from the TARGET-FIRST clinical trial, demonstrating that patients with low-risk myocardial infarction require only one month of dual antiplatelet therapy when implanted with Firehawk® Stents, reducing bleeding complications by 54%. This significant recognition highlights the Firehawk® Stent’s potential to transform global clinical practices, emphasizing its high quality, cost-effectiveness, and accessibility, and reinforcing MicroPort’s commitment to advancing cardiovascular treatment strategies.
The most recent analyst rating on (HK:0853) stock is a Buy with a HK$17.20 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
More about MicroPort Scientific
MicroPort Scientific Corporation is a company focused on developing innovative medical devices and technologies, particularly in the cardiovascular field. Their primary product, the Firehawk® Stent, is a third-generation coronary drug-eluting stent system known for its low restenosis rate and extremely low late stent thrombosis rate. The company aims to ensure that Chinese-made products are recognized globally, backed by robust clinical evidence.
YTD Price Performance: 89.51%
Average Trading Volume: 44,895,730
Technical Sentiment Signal: Buy
Current Market Cap: HK$22.52B
See more insights into 0853 stock on TipRanks’ Stock Analysis page.